Home » Posts tagged 'research'
Tag Archives: research
#TEK Tek Capital PLC – US Salt forms Strategic Partnership with MicroSalt
Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that MicroSalt has entered into an agreement with US Salt LLC (“US Salt”) for the distribution and delivery of MicroSalt’s low-sodium solutions.
“We are proud to work with US Salt in their efforts to offer low-sodium solutions to their customer base. US Salt as a leader in salt distribution, offering lower sodium as an active option in its ingredient listing. Excess sodium intake is one of the world’s leading health concerns, and we believe that partnerships like this are a great way to expand our efforts to address the sodium reduction challenge.” Said Rick Guiney, CEO of MicroSalt”
“US Salt is looking forward to working with MicroSalt® to help with our low-sodium initiatives. Sodium is a worldwide concern in the food industry, and we believe Rick and his team are the industry leaders that can help propel our future growth.” Said Bob Jordan, Vice President of Sales & Marketing of US Salt LLC.
This partnership is expected to strengthen each companies’ respective market positions as leaders in the sodium reduction effort, through expanding the customer base for MicroSalt and the product offerings for US Salt, with healthy, lower sodium alternatives.
About US Salt LLC
US Salt, LLC is currently responsible for producing and distributing over 90% of the private label, round can salt business in the United States. US Salt currently produces and packs 26-ounce private label table salt, as well as a complete portfolio of quality round can table salt items to meet all salt seasoning needs. To learn more about US Salt, visit www.ussaltllc.com.
About MicroSalt, Ltd
MicroSalt, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples’ lives with better-for-you seasonings and snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavour because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.
To learn more about MicroSalt please visit www.microsaltinc.com
To learn more about SaltMe! snacks please visit www.saltme.com/
Tekcapital owns 97% of the share capital of MicroSalt Ltd. and 6,034,683 shares (78%) of MicroSalt Inc., its U.S. subsidiary.
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
.
LEI: 213800GOJTOV19FIFZ85
For further information, please contact:
|
Tekcapital Plc |
Via Flagstaff IR |
|
|
Clifford M. Gross, Ph.D. |
||
|
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
+44 (0) 20 3470 0470 |
|
|
Richard Morrison / Charlie Bouverat (Corporate Finance) Rob Rees (Corporate Broking)
|
||
|
Flagstaff Strategic and Investor Communications Tim Thompson/Andrea Seymour/Fergus Mellon
|
+44 (0)207 129 1474 |
#TEK Tekcapital Plc – Appointment to the Board of MicroSalt
Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that Judith Batchelar OBE has joined the board of MicroSalt.
Judith currently serves as Deputy Chair of the U.K. Environment Agency, sits on UK Research and Innovation’s Natural Environment Research Council and is a Trustee of the Royal Botanic Gardens Kew. She has worked in the food and drink industry for over 35 years. From 2004 to 2021, she worked for Sainsbury’s as Director of Sainsbury’s Brand with responsibility for all aspects of Sainsbury’s product offer.
Prior to Sainsbury’s, Judith held a similar role at Safeway, spent twelve years in the Food Division at Marks & Spencer, and prior to this worked in manufacturing for Mars and Bass.
Judith is a biochemist and a nutritionist, has an Honorary Doctorate in Agriculture from Harper Adams University, and is a Fellow of the Institute of Food Science and Technology (IFST), and the Royal Society of Arts and Manufactures (RSA).
Judith was awarded an OBE in 2015 for services to Farming and the Food Industry, and serves on the Food, Farming and Countryside Commission.
“We are very excited to have Judith join our team. Her deep industry experience in improving the nutritional profile of foods will be enormously helpful with our go-to-market efforts in the U.K.,” said Rick Guiney, CEO of MicroSalt®.
Commenting on her appointment Judith Batchelar said, “I’m really excited to join the board of MicroSalt, I am passionate about their mission to help combat cardiovascular disease by reducing sodium levels in the foods we eat, and I know we can make a difference. “
About MicroSalt®
MicroSalt, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples’ lives with better-for-you seasonings and snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavour because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.
To learn more about MicroSalt please visit https://www.microsaltinc.com
Tekcapital owns 97.2% of the share capital of MicroSalt Ltd. and 73% of MicroSalt Inc. its U.S. subsidiary.
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
LEI: 213800GOJTOV19FIFZ85
For further information, please contact:
|
Tekcapital Plc |
Via Flagstaff IR |
|
|
Clifford M. Gross, Ph.D. |
||
|
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
+44 (0) 20 3470 0470 |
|
|
Richard Morrison / Charlie Bouverat (Corporate Finance) Rob Rees (Corporate Broking)
|
Flagstaff Strategic and Investor Communications +44 (0)207 129 1474
Tim Thompson/Andrea Seymour/Fergus Mellon
#ORPH Open Orphan PLC – Director dealings
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has received notification that on 29 September 2022, Yamin ‘Mo’ Khan, Chief Executive Officer of the Company, purchased 510,204 ordinary shares of 0.1 pence each in the capital of the Company (“Shares”) at a price of 9.8 pence per Share. Following the purchase of shares Mo holds 510,204 ordinary shares representing approximately 0.08 per cent of the Company’s issued ordinary capital.
Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan plc, said: “The purchase of shares in the Company demonstrates both my commitment and my confidence in our long-term growth strategy. Since my appointment as CEO in February 2022, we have made significant progress, delivering continued growth and a record orderbook valued at c.£80m as of 1 September, which provides excellent forward visibility into H2 2022 and 2023.”
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) (“MAR”). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
For further information please contact:
|
Open Orphan plc |
+44 (0) 20 7756 1300 |
||
|
Yamin Khan, Chief Executive Officer |
|||
|
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
|
Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King |
|||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash / James Thompson / Richard Chambers |
|||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
|
Anthony Farrell |
|||
|
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage / |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / |
||
#POLB Poolbeg Pharma PLC – HC Wainwright Global Investment Conference
12 September 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in New York City, NY, USA.
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 20 7183 1499 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard Chambers, Sunila de Silva (ECM), Nigel Birks
|
+44 (0) 20 7220 0500 |
|
Singer Capital Markets (Joint Broker) Phil Davies, Sam Butcher
|
+44 (0) 20 7496 3000 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field
|
+44 (0) 20 7457 2020
|
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a unique capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for pharma and biotech seeking mid-stage products to license or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with initial results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) programmes to accelerate the power of its human challenge model data and biobank, with results from the first programme expected by year end 2022.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
#BRES Blencowe Resources – Research Note
Blencowe Resources (“Blencowe” or the “Company”) (BRES:LON), is pleased to note the publication of a new research note by First Equity Limited on the Company’s Orom-Cross graphite project, located in Uganda.
In the note, First Equity Limited, using the new PFS numbers, have updated their risked valuation model, based upon a revised NPV8 of $482m for Orom-Cross and by applying a 30% development/resource, 50% finance and 25% country risk factors to derive an estimated £105.4m (prev. £43m) value.
A £105.4m risked graphite project value equates to a price per share of 59p, which is more than double their previous 27p target and represents an uplift of around 18 times from the current share price.
Click here to read: https://blencoweresourcesplc.com/capital-structure/
**ENDS**
Contacts
|
Blencowe Resources Plc
Sam Quinn (London Director)
|
+44 (0)1624 681 250 info@blencoweresourcesplc.com
|
|
Investor Enquiries Sasha Sethi
|
Tel: +44 (0) 7891 677 441 sasha@flowcomms.com
|
|
Tavira Securities Jonathan Evans
|
Tel: +44 (0)20 7100 5100 jonathan.evans@tavirasecurities.com |
|
First Equity Limited Jason Robertson |
Tel: +44 (0)20 7330 1883 jasonrobertson@firstequitylimited.com |
#ANA Ananda Developments – Shareholder Update
Ananda’s ambition is to be a leading UK grower and provider of high quality, consistent, carbon zero medical cannabis for the UK and international markets.
The Directors of Ananda provide the following update to shareholders.
Research programme
In early February 2022, 5 seeds of each of 13 strains of cannabis were planted at the DJT Plants Limited (“DJT”) medical cannabis research facility. Since then, the DJT team has been undertaking the following activities:
- The cannabis plants have been monitored daily, water requirements and nutrient requirements have been logged, and notes regarding the growth performance of each plant has been recorded.
- Pruning has been undertaken to encourage the even growth of a larger number of branches of each plant.
- Continued drafting of relevant Standard Operating Procedures (SOPs) to ensure best practice.
The seeds planted comprise a range of high THC / low CBD strains, low THC / high CBD strains and balanced strains. The precise cannabinoid and terpene profile of each strain will be ascertained when the plants are sent for analysis to Israel and UK based labs.
The next step to achieve stable strains of cannabis for potential commercial growing will be for 9 cuttings to be taken from each plant. These cuttings will be used for:
- Planting in the multi chapelles to start to assess the performance of the strains in DJT’s specialised growing conditions.
- Planting in the mother room so that there is a supply of mother plants which can then be compared with later generations of the same strain.
- The self-crossing programme in which some of the plants are forced to become males and then to pollinate the female plant from the same seed. This will increase the genetic stability of the next generation of plants.
There are a number of other parts to the research programme which are all designed to assist in the growing of stable strains of medical cannabis with cannabinoid and terpene profiles found to be beneficial in the treatment of a range of conditions. A further update on these initiatives will be provided in due course.
Commercial growing
As the research programme progresses, the team is now focused on developing its commercial plans. Commercial growing and selling is dependent on the successfully receipt of further licences from the Home Office and GMP (Good Manufacturing Practice) certification from the Medicines and Healthcare products Regulatory Agency (MHRA).
DJT Plants has retained a best-practice international GMP and pharmaceutical consulting firm with experience in designing GMP compliant medical cannabis facilities in jurisdictions with regulations similar to the UK. They will assist in the design of DJT’s cannabis manufacturing facility. As the UK is in the early years of its medical cannabis industry, it is the opinion of DJT’s management team that an internationally experienced consultancy is best placed to assist DJT. The conceptual manufacturing flowsheet has been created by DJT and activities will now proceed to the more rigorous planning and design processes to ensure optimum workflows, ease of access from the commercial growing areas and scalability. The proposed facility will operate to GMP and will be fully compliant under the MHRA guidelines.
Corporate
There remains one outstanding item to complete the Circular to shareholders for the purchase of the 50% of DJT not owned by Ananda. Once final sign off is obtained, the Circular will be posted to shareholders and the relevant General Meeting called.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
| ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
| PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Corporate Broking |
+44 (0)20 7469 0930 |
Alan Green covers #MNRG MetalNRG and #COIN Coinisilium on this week’s Stockbox Research Talks
Alan Green covers #MNRG MetalNRG and #COIN Coinisilium on this week’s Stockbox Research Talks
Listen to the podcast here
#ORPH Open Orphan Plc – $13.4m Influenza HCS contract win
(AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan plc, has signed a $13.4m contract with a US-based biotechnology company to test its novel antiviral candidate using the hVIVO Influenza Human Challenge Study Model.
The study is expected to commence in H2 2022 and will be conducted at hVIVO’s state-of-the-art quarantine facilities in London. The Company expect the majority of revenues to be recognised in 2022.
The Company expects to sign an increasing number of contracts in this area as the global pandemic has highlighted the increased investment needed from governments and Big Pharma to develop effective, novel treatments for a range of infectious diseases that have potential to cause the next pandemic. Influenza is one such disease, with emergences of flu pandemics impossible to predict. Symptoms of influenza may be mild or cause severe disease, or in certain cases, death. Influenza is a serious global health threat with an estimated 1 billion cases per year, 3-5 million severe cases and 290,000 – 650,000 deaths per year.
hVIVO has two decades of experience and expertise in safely conducting challenge studies across a range of respiratory viruses, including various strains of influenza, respiratory syncytial virus (RSV), human rhinovirus (HRV – common cold virus), malaria, and asthma. In October 2020, this expanded to include the SARS-CoV-2 virus.
Cathal Friel, Executive Chairman of Open Orphan, said : ” We are delighted to announce this significant challenge study contract valued at over £10m, with a US-based biotechnology client testing its highly promising influenza antiviral candidate. This contract demonstrates the Company’s continued ability to convert its leading portfolio of challenge study models into substantial contracts, with signed contracts across a number of our challenge study models including RSV, asthma, hRV, and flu in the clinic next year. This underlines our market position as the world leader in the testing of vaccines, antivirals and respiratory products using human challenge trials.
“The recent emergence of the Omicron variant has illustrated the threat of pandemic infectious diseases, and as a result, pharma companies globally are looking to address the next cohort of infectious diseases which have potential to reach pandemic level, and are developing new therapeutics to help tackle them. Influenza is high on this list, and we expect to sign more contracts of this type as the infectious disease market grows exponentially in the coming years to be worth $250 billion by 2025. “
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) (“MAR”). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com . By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.
Individuals interested in taking part in COVID-19 human challenge study research can learn more at www.UKCovidChallenge.com .
For further information please contact:
|
Open Orphan plc |
+353 (0) 1 644 0007 |
|||
|
Cathal Friel, Executive Chairman |
||||
|
Arden Partners plc (Nominated Adviser and Joint Broker) |
+44 (0) 20 7614 5900 |
|||
|
John Llewellyn-Lloyd / Louisa Waddell |
||||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
|||
|
Geoff Nash / James Thompson/ Richard Chambers |
||||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
|||
|
Anthony Farrell |
||||
|
Walbrook PR (Financial PR & IR) |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com |
|||
|
Paul McManus/ Sam Allen/ Louis Ashe-Jepson |
+44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 |
|||
#POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate
6 December 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor Siobhán McClean , through NovaUCD, the university’s knowledge transfer office.
The Company will continue its due diligence on MelioVac, a preclinical asset and recipient of a Wellcome Trust Award to aid its development, as well as 5 of other potential vaccine candidates discovered by Associate Professor McClean and her team, for the duration of the Option Agreement, prior to signing a ‘Licence Agreement’.
Dr McClean is Associate Professor and Head of Biochemistry at the UCD School of Biomolecular and Biomedical Science. Dr McClean completed her BSc in Biochemistry in UCD and received her PhD from Imperial College London. Her research focuses on lung infections which led her to develop a platform technology to identify proteins that bacteria use to attach to human cells. These proteins have proved to be excellent vaccine candidates. Dr McClean completed some of the original research to identify the antigens associated with the Melioidosis Vaccine at TU Dublin.
Poolbeg Pharma has identified melioidosis as an infectious disease of interest due to its rising incidence around the world and because there is currently no approved vaccine available. Concerns are growing about global warming contributing to the spread of the disease to traditionally non-tropical areas.
Melioidosis, also known as Whitmore’s disease, is an infectious disease caused by the bacterium Burkholderia pseudomallei, commonly found in the soil and surface groundwater of many tropical and subtropical regions, with diverse clinical presentations including pneumonia and severe sepsis with multiple organ abscesses. Incidence of the disease is widespread in South-East Asia, Northern Australia and India, with climate change having a substantial impact on the spread of the disease to new areas such as Brazil. There are an estimated 165,000 cases of melioidosis each year, of which as many as 89,000 (54%) are estimated to be fatal.
Other potential vaccine candidates that the Company is evaluating include those for Klebsiella pneumoniae,Escherichia coli (O157), Burkholderia cepacia complex, Pseudomonas aeruginosa and Acinetobacter baumannii.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“Melioidosis offers Poolbeg an opportunity to expand our portfolio of infectious disease assets, as promised at IPO. This is a disease which presents a dangerous and underappreciated threat to human health which currently has no approved vaccine and a very high mortality rate. If we can take MelioVac through clinical development to Phase II ready, it has the potential to generate significant returns for investors in the short-term while contributing to the global response to the threat of infectious diseases with an unmet medical need. We are excited by the potential of the MelioVac opportunity along with the other vaccine candidates in the UCD portfolio.”
Siobhán McClean, Associate Professor at the UCD School of Biomolecular and Biomedical Science and inventor of MelioVac , said:
“We are passionate about developing a vaccine against Melioidosis. Poolbeg Pharma is a great potential partner to work with, bringing its experience of vaccine development and industry connections to our innovative science. On the basis that a license is taken, it would be a great to see the development of MelioVac and other candidates, and contribute significantly to the world’s renewed fight against infectious diseases.”
– Ends –
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) (“MAR”). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+353 (0) 1 644 0007 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard Chambers, Sunila de Silva (ECM)
|
+44 (0) 20 7220 0500 |
|
Arden Partners PLC (Joint Broker) John Lewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field |
+44 (0) 20 7457 2020 poolbeg@instinctif.com |